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A new target region for changing 
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Yuehua Zhi1, Feng Hou1, Noriyuki Ito3, Akira Iwasaki4, Yoshihiko Yasohara3 & 
Masaru Tanokura1
(R)-stereospecific amine transaminases (R-ATAs) are important biocatalysts for the production of 
(R)-amine compounds in a strict stereospecific manner. An improved R-ATA, ATA-117-Rd11, was 
successfully engineered for the manufacture of sitagliptin, a widely used therapeutic agent for 
type-2 diabetes. The effects of the individual mutations, however, have not yet been demonstrated 
due to the lack of experimentally determined structural information. Here we describe three crystal 
structures of the first isolated R-ATA, its G136F mutant and engineered ATA-117-Rd11, which 
indicated that the mutation introduced into the 136th residue altered the conformation of a loop next 
to the active site, resulting in a substrate-binding site with drastically modified volume, shape, and 
surface properties, to accommodate the large pro-sitagliptin ketone. Our findings provide a detailed 
explanation of the previously reported molecular engineering of ATA-117-Rd11 and propose that the 
loop near the active site is a new target for the rational design to change the substrate specificity of 
ATAs.
Pure chiral amines, especially the R-amines, are crucial building blocks in the synthesis of certain phar-
maceutical drugs such as Cinacalcet used to treat secondary hyperparathyroidism1, an active ingredient 
Sitagliptin2 for diabetes mellitus type 2, Silodosin for the symptomatic treatment of benign prostatic 
hyperplasia3, Tamsulosin used in the treatment of difficult urination4, Formoterol for the management of 
asthma and chronic obstructive pulmonary disease5 and antihistamine Levocetirizine6. Amine transam-
inases (ATAs), trivially referred to as amine-pyruvate transaminases, have been a focus of increased 
attention due to their ability to synthesize pure chiral amines as promising biocatalysts. ATAs trans-
fer an amino group of a chiral amine compound to a ketone compound using the cofactor pyridoxal 
5’-phosphate (PLP) (Supplementary Fig. 1a) with a high turnover rate, stable catalytic activity, broad sub-
strate specificity and excellent stereoselectivity7, which is achieved by a proposed large-binding pocket (L 
pocket) and small-binding pocket (S pocket) in the substrate-binding site8–16 (Supplementary Fig. 1b). 
This transfer ability could allow ATAs to overcome the shortcomings of chemical syntheses, such as harsh 
reaction conditions, effluent of toxic catalytic metal, and even insufficient enantiopurity17.
The first R-ATA, which was identified from Arthrobacter sp. KNK168 (FERM-BP-5228) (Ab-R-ATA) by 
enrichment screening, showed activity on primary amine and methyl ketones or small cyclic ketones18,19. 
Ab-R-ATA was successfully applied to the asymmetric synthesis of several kinds of chiral amines, such as 
(R)-dimethoxyamphetamine (DMA), (R)-4-methoxyamphetamine, (R)-1-(3-hydroxyphenyl) ethylamine 
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and (R)-1-(3-methoxyphenyl) ethylamine20. A report on the purification, characterization, and gene 
cloning of Ab-R-ATA published recently21,22. Höhne et al. discovered 20 R-ATAs using an in silico search 
strategy based on the analysis of amino acid sequences of typical motif for R- and S-ATAs23. Some of 
the identified R-ATAs are under investigation on the substrate specificity and reaction conditions24. An 
improved R-ATA, designated as ATA-117-Rd11 was derived from ATA-117, a homolog of Ab-R-ATA, by 
the substrate walking approach for use in the synthesis of sitagliptin, on an industrial scale25,26, whereas 
both Ab-R-ATA and ATA-117 could not produce such a large compounds (Supplementary Fig. 1c). 
ATA-117-Rd11 achieved a 13% increase in yield and a 19% reduction in total waste, which ultimately 
reduced the production cost when compared to the chemical approach used to synthesize sitagliptin9. 
The series of studies on R-ATAs are widely regarded as a significant milestone in the history of enzyme 
application and engineering27–29. These breakthrough researches should be further investigated by exper-
imental structural studies to more deeply elucidate the mechanism underlying the substrate specificity 
and/or stereospecificity of ATAs.
Up to now, several structures of S-ATAs9–12 and R-ATAs13–16 have been determined, providing some 
information about the dual substrate recognition30 of ATAs, which is a unique ability of transaminases 
to accept both the hydrophilic and hydrophobic substrates in the same active site. In the S-ATAs, a 
“flipping” arginine residue in a loop near the active site was proposed to play a key role in dual sub-
strate recognition by moving the guanidino group in the active site to interact with the carboxylate of 
substrates or moving out of the active site to provide a hydrophobic environment9. Recently, R-ATAs 
from Aspergillus terreus, Nectria haematococca and Aspergillus fumigatus were reported and an arginine 
residue near the active site was assumed to possess the similar function, binding carboxylated groups, 
as that in the S-ATAs14–16.
Although several structures of S-ATAs and R-ATAs are already available, the structural basis for 
the substrate specificity and enantioselectivity of the engineered ATA-117-Rd1125,26 has not been elu-
cidated yet. The molecular engineering of ATA-117-Rd11 should be reevaluated by structural study of 
the enzyme because, once a protein engineering is rationalized by experimental structural information, 
the extensive data gathered during the engineering process and the essence extracted from the data 
may be widely applied to some other enzymes and will drive researches on enzyme engineering. Here 
we show three crystal structures of the wild-type Ab-R-ATA, its G136F mutant, and ATA-117-Rd11, 
along with mutational and computational analysis. In this study, we used Ab-R-ATA instead of ATA-
117, the parental enzyme of ATA-117-Rd11, and could elucidate a reasonable molecular mechanism 
underlying the engineering of ATA-117-Rd11 because the difference between Ab-R-ATA and ATA-117 
is only the amino acid residue at position 306 (Val and Ile in Ab-R-ATA and ATA-117, respectively) far 
from the active site, which is supposed to have negligibly small effect on the substrate recognition and 
activity and is not conserved in R-ATAs. In addition, the 306th residue and the residues around it were 
not included in any round of evolution during the engineering. The G136F mutant was derived from 
structural comparison between Ab-R-ATA and ATA-117-Rd11, where the 136th residue was considered 
as the main cause of the structural alteration of the loop near the active site as will be described. These 
results would provide the molecular basis for the conversion of the substrate specificity of ATAs, which 
are highly valuable biocatalysts.
Results
Overall structures. The crystal structures of the wild-type Ab-R-ATA, the G136F mutant of 
Ab-R-ATA and ATA-117-Rd11 were determined at 1.65-Å, 2.27-Å, and 2.20-Å resolutions, respectively 
(Supplementary Table 1). These structures are very similar to each other (RMSD of Cα atoms less than 
0.38 Å). Each protomer (subunit) of the dimeric enzymes shows a structural architecture typical of 
the fold-type IV class of PLP-dependent enzymes, which are made up of two domains (Fig.  1a and 
Supplementary Fig. 2). The substrate-binding site is surrounded by the cavity among the two domains, 
the cofactor PLP (Supplementary Fig. 3), and the loop consisting of the residues 129–145 of the other 
protomer (Fig. 1a). The substrate-binding site can be divided into two parts as described initially, the L 
pocket and the S pocket (Fig. 1b), which is consistent with the previously proposed mechanism for the 
substrate specificity of ATAs in which the smaller and larger atomic groups of substrates are recognized 
by the S and L pockets, respectively8. The results of docking simulations using these crystal structures 
supported the mechanisms (Supplementary Fig. 4).
Arg138 in the loop 129-145 of Ab-R-ATA concerns dual substrate recognition. The models 
complexed with a glycerol molecule at the active site of Ab-R-ATA (Supplementary Fig. 5) suggested 
that Arg138 of the wild-type Ab-R-ATA is important for the recognition of probable native substrates, 
such as pyruvate. This suggestion was supported by site-directed mutagenesis analyses. The kcat/Km values 
for pyruvate of the R138A and the R138Q mutants, using (R)-1-phenylethylamine as the amino donor, 
were about 350-fold and 500-fold lower than that of the wild-type Ab-R-ATA, respectively, indicating 
that the side chain of Arg138 is important for the recognition of pyruvate (Supplementary Table 2). The 
importance of Arg138 in the pyruvate recognition was also supported by molecular dynamics (MD) 
simulations of the wild-type Ab-R-ATA complexed with PMP-pyruvate quinonoid intermediate. During 
the simulation, the carboxyl group of the quinonoid intermediate formed a stable salt bridge with gua-
nidinium group of Arg138 (Supplementary Fig. 6).
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Figure 1. Structural architecture of R-ATAs and structural conversions in the loop 129-145. (a) The Ab-
R-ATA dimer. A protomer is shown as a ribbon and the other as the surface. The large and small domains 
are colored in cyan and magenta, respectively, except for the loop 129–145, which is colored in red. (b) The 
L pocket and S pocket in the active site. The cyan mesh represents the cavity of the active site. PLP and the 
side chain of Lys188 are shown as sticks. The loop 129–145 and Arg138 from the neighboring protomer 
are shown as a red ribbon and stick, respectively. (c) Structural comparison among the loops 129–145. 
The backbone trace around the loops 129–145 of Ab-R-ATA, the mutant G136F, and ATA-117-Rd11 are 
shown in cyan, orange, and yellow, respectively. The residues 136 and 138 and PLP are shown as sticks. The 
neighboring protomer of Ab-R-ATA is shown as a white surface with a red substrate-binding site. (d) Stereo 
view showing the probable conformational change of loop 129–145. A steric hindrance occurred between 
Phe136 and Val152 once Gly136 of Ab-R-ATA (cyan) was manually mutated to phenylalanine (white) in its 
energy-favorable rotamer. To avoid this steric hindrance, the loop changes its conformation to that of the 
G136F mutant (orange). (e) Enlargement of the L pocket caused by the mutation of G136F. The cavity of 
Ab-R-ATA and the G136F mutant are shown as cyan and orange mesh, respectively. (f) Close-up view of the 
residue Phe136 in ATA-117-Rd11. The van der Waals radii of the side chains of Phe136, Ile199, Leu209 and 
Pro223 are represented as yellow dots. (g to i) Changed position of the L and S pockets. The docking models 
of the methyl ketone analog docked into Ab-R-ATA (g) or the G136F mutant (h), and pro-sitagliptin ketone 
docked into the ATA-117-Rd11 (i) are shown. The parameters for cavity-detection and presentation are 
consistent among these three panels.
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Ab-R-ATA can also transfer amino group to the ketones with highly hydrophobic larger substituents 
(RL), such as benzylacetone. The specific activity of the R138A and the R138Q mutants towards ben-
zylacetone, using (R)-1-phenylethylamine as the amino donor, decreased to 50% and 23%, respectively, 
as the results of the mutations (Supplementary Table 2), indicating that the Arg138 residue plays an 
important role when Ab-R-ATA forms the complex with benzylacetone, although the details remained 
to be established.
Significantly different conformations in the loop 129-145. The loops 129–145 of the G136F 
mutant and ATA-117-Rd11 showed significantly different conformation from that of the wild-type, 
depending on the amino acid residue at the position 136 (Fig. 1c, Supplementary Figs. 7-8). Gly136 was 
located near Val152 in the wild-type, whereas Phe136 was distant from Val152 in the G136F mutant and 
ATA-117-Rd11, accompanied by the long-range alteration of the loop’s backbone conformation (Fig. 1d). 
This suggests that the probable steric hindrance between the bulky side chain of Phe136 and Val152 was 
the main cause of the conformational difference. The G136F/Y/H/W mutants show more than 40-fold 
lower kcat/Km values towards pyruvate (Supplementary Table 2), indicating that these mutants could not 
recognize pyruvate properly. This is probably due to the introduction of a bulky side chain into the res-
idue 136, which could have altered the conformation of the loop 129–145, and thus caused Arg138, the 
key residue for pyruvate recognition, to move out from the active site (Fig. 1c).
Structural conversions located beyond the loop 129-145. Cumulative mutations on the 
substrate-binding site served to enlarge its volume and change its surface properties. Based on the results 
of activity detection of the engineering study, the truncation of Phe122 and either Val69 or Ala284 of 
ATA-117 is adequate for accommodating the 1,2,4-3-fluorine phenyl group of pro-sitagliptin ketone25,26. 
In the final biocatalyst ATA-117-Rd11, Val69, Phe122, and Ala284 (in the S pocket of Ab-R-ATA) were 
mutated to Thr, Met, and Gly, respectively. Comparison of the active site pockets of the Ab-R-ATA and 
ATA-117-Rd11 shows that the volume of S pocket is enlarged by the three mutations (Fig.  2a–b). The 
mutation of V69T, which does not seem to contribute to the change in the volume of the substrate-binding 
site, may contribute to the stability of the enzyme, since mutations including the 69th residue allowed 
the enzyme to react under more harsh conditions25. Similarly, His62 (in the L pocket of Ab-R-ATA) was 
mutated to Thr to increase the volume of the active site around it by reducing the volume of the amino 
acid side chain (Fig. 2c).
Discussion
Dual substrate recognition is a characteristic of ATAs. Both the hydrophilic and hydrophobic groups of 
substrates can be bound to the same L pocket of ATAs. For S-ATAs, as mentioned in the introduction, 
Figure 2. Structural conversions located beyond the loop in the molecular engineering to produce 
sitagliptin. (a and b) Enlargement of the S pocket caused by the four mutations in the active sites. Stereo 
view of the surface is shown for Ab-R-ATA (a) and ATA-117-Rd11 (b) The locations of the four residues are 
shown in red and labeled. (c) Enlargement of the L pocket (semi-circle labeled L) caused by the mutation 
H62T. His62 (in the L pocket of Ab-R-ATA) was mutated to Thr, reducing its size and increasing the volume 
of the active site around it. The active site cavities of Ab-R-ATA (cyan) and ATA-117-Rd11 (yellow) are 
shown as mesh. The semi-circle-labeled S represents the enlarged S pocket mentioned in (b).
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the dual substrate recognition is achieved via the conformational change of a “flipping” arginine residue 
in a loop near the active site9. For R-ATAs, similarly, an arginine residue near the active site was sup-
posed to show the similar function to that in the S-ATAs14–16; Arg126 in the R-ATA from Nectria hae-
matococca or Aspergillus fumigatus and the Arg128 in the R-ATA from Aspergillus terreus. Although the 
corresponding arginine residue is not conserved in Ab-R-ATA (Supplementary Fig. 9), the guanidinium 
group of Arg138 of Ab-R-ATA was located near the position where the guanidinium groups of those 
arginine residues in the other R-ATAs (Supplementary Fig. 10). In addition to this structural similarity, 
Arg138 of Ab-R-ATA was proven to recognize the carboxyl group of pyruvate by kinetic analysis and MD 
simulation, suggesting that Arg138 is the compensation for the key arginine residue of the other ATAs.
However, in contrast to that in the S-ATAs, the corresponding arginine residues in the R-ATAs did 
not show any flipped conformation. Instead, two conformations of an active site loop (corresponding to 
the loop of Arg129-Pro145 of Ab-R-ATA) containing the notable arginine residue in the R-ATA from 
Aspergillus fumigatus were observed14. In the “open” conformation, the active site loop moved out of the 
active site and stabilized by the hydrogen bond between Arg126 and Asp132 residues, which probably 
could provide more space and stronger hydrophobic environment to accommodate a bulky hydrophobic 
substrate. Although a similar loop conformation was not observed in the structure of Ab-R-ATA, it can 
be supposed to exist during the reaction, stabilized by the interaction between Arg138 and some negative 
charged side chains or the carbonyl group of main chain. This hypothesis can explained our results of 
activity measurements of the R138A and the R138Q mutants toward benzylacetone. When Arg138 was 
mutated to alanine or glutamine, the interaction that could maintain the loop 129–145 in an “open” con-
formation became weak so that the loop may adopt the conformation in the crystal structure, which is 
unfavorable for benzylacetone binding. Thus, the specific activities of the R138A and the R138Q mutants 
towards benzylacetone were decreased. It is noticeable that, from the discussion above, the dual substrate 
recognition mechanism of R-ATAs probably differs from that of S-ATAs. R-ATAs alter the conformation 
of the active site loop containing an arginine residue, while S-ATAs flip a single arginine residue.
The molecular engineering of ATA-117-Rd11 involved 27 mutations (Fig. 3a–c) that made this ATA 
conquer the severe reaction problems in the realistic industrial production, such as a high concentration 
of organic solvent, a high temperature for enhancing the solubility of prositagliptin ketone, and a high 
concentration of amine donor isopropylamine for prompting the product accumulation25,26. Another 
notable point is that the high stereoselectivity was not lowered by the 27 mutations25,26. Based on the pre-
vious engineering study and the crystal structures in the present study, the 27 mutations can be divided 
into three kinds of structural modifications: 1) alteration of the conformation of the loop 129–145, 2) 
clipping or replacement of the side chains of the residues composing the substrate-binding site (including 
the L or S pockets), and 3) modifications of residues out of the substrate binding pockets for improving 
biochemical characteristics (Fig. 3d). Among these three kinds of modifications, the first and second can 
be explained by our crystal structures.
As described above, the alteration of the loop 129–145 varied the properties of the substrate bind-
ing site drastically. The residue 136 was moved into the L pocket by the alteration of the loop, leading 
to a probable hydrophobic interaction between Phe136 and the cyclic group of pro-sitagliptin ketone 
(Fig. 3d). Simultaneously, Arg138 was moved away from the substrate-binding site by the alteration of 
the loop, resulting in an enlargement of the cavity to accommodate large substrates (Fig. 1e). These con-
clusions could well explain how the G136F/Y/H/W mutants favor bulky and hydrophobic substrates. In 
addition, along with the other structural modifications, the position of the L pocket shifted (Fig. 1g–i). 
Ser223 (in the L pocket of Ab-R-ATA) was mutated to Pro, resulting in an additional interaction, a van 
der Waals interaction among the side chains of Phe136, Ile199, Leu209, and Pro223, which would have 
stabilized the conformation of the loop 129–145 (Fig. 1f). To sum up these mutational effects, the volume 
of the substrate-binding site was drastically enlarged by the alteration of the loop 129–145 and the other 
mutations, and the position of the L pocket was shifted by the alteration of the loop 129–145. Based on 
these results, we propose that the loop 129–145 mainly determines the substrate specificity of Ab-R-ATA, 
although cumulative mutations on the substrate-binding site also serve to enlarge its volume and change 
its surface properties (Fig. 2).
From the alignment of Ab-R-ATA and eight R-ATAs recently identified13,23, most of the residues that 
make up the substrate-binding site of Ab-R-ATA are conserved in the other seven enzymes, whereas the 
residues in the loop 129–145 are not conservative (Fig. 4a–b and Supplementary Fig. 9). The difference 
among the substrate specificities of the seven newly discovered R-ATAs is discussed based on the phy-
logenetic relationship among them, and R-ATAs from Aspergillus terreus and Penicillium chrysogenum 
showed distinct specificity although they have high similarity score in multiple alignments24. There is 
only one different residue in the loop between them. Meanwhile, another two R-ATAs from Aspergillus 
fumigatus and Neosartorya fischeri with the same sequence in the loop showed nearly the same substrate 
specificity24. Thus, it is reasonable to assume that the diversity of the amino acid sequence of the loop 
causes the different substrate specificity among these enzymes, in accordance with the present model, 
in which the loop 129–145 is the main determinant of the substrate specificity of R-ATA. The recently 
determined crystal structures of R-ATAs13–16 show different conformations of the corresponding loop 
(Fig. 4c) from that of Ab-R-ATA and ATA-117-11Rd, supporting our suggestion that the loop’s confor-
mation can vary depending on the amino acid sequence. In addition, mutation of the residues Phe3, 
Pro48, Tyr150, Gln155, Val199, and His203, which exist around the loop 129–145 (Fig.  4a), are also 
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expected to change the conformation of this loop. As a conclusion, the loop 129–145 functions as a 
substrate-specificity determinant, and this loop and its surrounding residues should be prioritized as 
research subjects when attempting to engineer R-ATAs to transform the substrate specificity.
Figure 3. Analysis of the previous molecular engineering of ATA-117. (a-c) Amino acid sequence 
comparison among Ab-R-ATA, ATA-117, and ATA-117-Rd11. The 27 mutations introduced in the previous 
successful engineering of ATA-117 on the molecular surface (a) or inside the molecule (b) are highlighted in 
red and labeled. Residue 306 is indicated by the dashed circle in (a) .The “N” in (b) represents the Val11 at 
the N-terminus. The unobserved Phe8 in ATA-117-Rd11 is probably away from the active site. The cofactor 
PLP in the active site is shown as green sticks. The table in (c) shows the differences of the amino acid 
residues among three R-ATAs. (d) A schematic diagram of the strategies in the engineering. The amino acid 
residues consisting of the L pocket and S pocket are represented in green and purple text boxes, respectively. 
Cofactor PMP and docked ligands are shown as sticks.
www.nature.com/scientificreports/
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Figure 4. Conservation of the residues in the active site and loop 129-145. (a) The amino acid residues 
on the molecular surface of Ab-R-ATA are colored turquoise to maroon according to the conservation 
grades shown on the color-coding bar, which range from variable to conservative. The conservativeness was 
evaluated by analyzing the aligned sequence of Ab-R-ATA and its seven homologs on the ConSurf server41,42. 
The seven homologs of Ab-R-ATA are from Aspergillus terreus (GI_115385557), Penicillium chrysogenum 
(GI_211591081), Aspergillus oryzae (GI_169768191), Aspergillus fumigatus (GI_70986662), Neosartorya 
fischeri (GI_119483224), Gibberella zeae (GI_46109768), Mycobacterium vanbaalenii (GI_120405468). (b) 
Logographical representations of the amino acid sequence conservation within loop 129–145 in Ab-R-ATA 
and the seven homologs. The height of each stack corresponds to the degree of sequence conservation at 
that position. The height of letters represents the relative frequency of individual amino acids at the position. 
Logo representations were obtained by using Weblogo. (c) R-ATAs showed different conformations of the 
corresponding loop 129–145. These loops of Ab-R-ATA, ATA-117-Rd11, R-ATA from Aspergillus terreus 
(PDB ID 4CE5), R-ATA from Aspergillus fumigatus (PDB ID 4CHI) and R-ATA from Nectria haematococca 
(PDB ID 4CMD) are shown in cyan, green, magenta, yellow and pink, respectively.
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Methods
Overexpression and purification. The Ab-R-ATA expression plasmid constructed by inserting the 
R-ATA gene from Arthrobacter sp. KNK168 (FERM-BP-5228) (GI_ 336088340) under the lac promoter 
of the pUCNT vector22 was used for transformation of Escherichia coli Rosetta (DE3) to overexpress 
Ab-R-ATA that contains 330 amino acids with no tag. The transformants were cultivated at 37 °C in 
Lysogeny broth (LB) medium containing 100 μ g/mL ampicillin. Overexpression was induced by adding 
1 mM isopropyl-β -D-thiogalactopyranoside (IPTG) when the optical density at 600 nm reached 0.6, and 
the culture was continued 20 hours at 20 °C. The expression plasmid for the G136F mutant of Ab-R-ATA 
was constructed using a PrimeSTAR Mutagenesis Basal Kit (Takara, Shiga, Japan). The DNA fragment 
containing the gene of ATA-117-Rd11 was synthesized (GenScript USA Inc.). The ATA-117-Rd11 gene 
was amplified with KOD-plus DNA polymerase (Toyobo, Tokyo, Japan) and inserted into the NdeI-SacI 
site of pET28a (+ ) to overexpress the fusion protein with an N-His tag. The G136F mutant and ATA-
117-Rd11 were expressed in the same way as Ab-R-ATA.
To purify Ab-R-ATA and the G136F mutant, the cells were resuspended in lysis buffer containing 
20 mM potassium phosphate buffer (pH 6.8), 0.01% 2-mercaptoethanol, 1 mM PLP and 10% (v/v) glyc-
erol. The cells were disrupted by sonication and centrifuged at 40000 g at 4 °C for 30 min. The supernatant 
was applied to a DEAE-Sepharose column, and the protein was eluted with 400 mM NaCl dissolved in 
buffer A containing 20 mM potassium phosphate buffer (pH 6.8) containing 1 mM dithiothreitol (DTT) 
and 10% (v/v) glycerol. The eluted protein with 1 mM PLP additive was dialyzed against buffer A. The 
dialyzate was applied to a 6 mL ResourceQ column (GE Healthcare) equilibrated with buffer A, and 
the protein was eluted with an NaCl gradient ranging from 0 to 1 M. The purified fractions were con-
centrated and loaded on an equilibrated Superdex 200 HR 10/30 column (GE Healthcare) and eluted 
with 20 mM potassium phosphate buffer (pH 6.8) containing 1 mM DTT and 5% (v/v) glycerol. The 
purified fractions were concentrated to 8 mg/mL using a Vivaspin-20 concentrator (10000 molecular 
weight cutoff). To purify ATA-117-Rd11, the supernatant after disrupting and centrifuging was applied 
to a Ni-Sepharose column, and ATA-117-Rd11 was eluted with 200 mM imidazole dissolved in buffer A. 
Before dialyzing against buffer A, 1 mM PLP and 500 U thrombin protease (GE Healthcare) were added 
into the eluted protein. The dialyzed protein was applied to a Ni-Sepharose column once again to remove 
the uncleaved protein. Subsequent ion exchange chromatography and size exclusion chromatography 
were performed as described above.
Crystallization. All crystallization experiments were performed at 20 °C by the sitting-drop 
vapor-diffusion method. The crystallization drops were prepared by mixing 2.0 μ L of protein solution 
and 2.0 μ L reservoir solution. After the crystallization conditions had been refined, crystals of Ab-R-ATA 
suitable for X-ray analysis were obtained using a reservoir solution consisting of 0.2 M magnesium chlo-
ride, 0.1 M Bis-Tris (pH 6.4), and 22% (w/v) PEG 3350. Before crystallization of ATA-117-Rd11, the 
protein storage buffer was changed to 20 mM Bis-Tris buffer (pH 6.8) containing 1 mM DTT and 10% 
(v/v) glycerol. By streak seeding, the crystals grew in one week. The crystallization drops were prepared 
by mixing 1.5 μ L protein solution (15 mg/mL) and 1.5 μ L reservoir solution (0.2 M magnesium chloride, 
0.1 M Tris-HCl (pH 8.3), 18% PEG 3350). Crystals of the G136F mutant of Ab-R-ATA grew in a drop 
containing 1.0 μ L protein solution (10 mg/mL) and 1.0 μ L reservoir solution (0.2 M magnesium chloride, 
0.1 M HEPES-HCl (pH 7.8), 16% PEG 3350) in 5 days.
Data collection and processing. The presence of glycerol and PEG 3350 under the crystallization 
condition alleviated the need for subsequent cryoprotection, and thus crystals were picked up in a nylon 
loop (Hampton Research) and directly flash-cooled in a nitrogen cryostream (100 K). The data sets for 
Ab-R-ATA, ATA-117-Rd11 and the G136F mutant were collected at beamlines BL-5A, AR-NW12A and 
BL-5A at the Photon Factory (Tsukuba, Japan), respectively. All data sets were composed of 360 images 
and collected using a 0.5° oscillation. All the diffraction data were indexed, integrated and scaled with 
XDSme31. Data-collection statistics are given in Supplementary Table 1.
Structure determination and refinement. The initial phasing of Ab-R-ATA diffraction data was 
conducted by molecular replacement using MOLREP32 in the CCP433 and with a single molecule of 
branched-chain amino acid aminotransferase as the search model (PDB 1IYE). The initial solution with 
one molecule in the asymmetric unit had starting Rwork and Rfree values in excess of 50%, which only 
dropped slightly, respectively, after refinement with Refmac534. The model was therefore improved using 
Buccaneer35 and ARP/wARP36, and these software successfully built most of the structure. The structure 
was then refined using Refmac5 and Phenix37 to obtain a model containing water with Rwork and Rfree 
values of 18.0% and 22.7%, respectively. The structure refinement was completed in Coot38 and Refmac5. 
The crystal structures of ATA-117-Rd11 and the G136F mutant were solved by molecular replacement 
using the structure of the Ab-R-ATA as a search model. The structures were manually rebuilt using Coot 
and refined using Refmac5.
Molecular docking. The docking simulations were performed using the software package MOE2011.10 
(Chemical Computing Group, Montreal, Canada). The dimers of the crystal structures of Ab-R-ATA, 
ATA-117-Rd11 and the G136F mutant with some modifications (the internal aldimines were changed 
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to lysine and PMP) were used as the receptor model. The missing hydrogen atoms of these dimers were 
generated and the energy was minimized using the Merck molecular force field 94x (MMFF94x) with 
distance-dependent dielectric electrostatics. The possible conformations of the methyl ketone analog and 
pro-sitagliptin ketone were generated using the systematic mode and used for the simulation. The two 
ligands were docked to each of the receptor models on the possible active sites, which were identified 
by the function Site Finder, using an Induced Fit protocol with default values for all parameters. The 
scoring function used by the Dock module of MOE is based on protein-ligand interaction energies. 
Solutions that met the following criteria were selected from the results of the Dock module of MOE and 
applied to the analysis: 1) the reactive keto group of the ligand points towards the -NH2 of PMP within 
an appropriate distance (less than 4.0 Å), and 2) the interaction energy and binding scores are favorable.
Molecular dynamics simulations. The model of the wild-type Ab-R-ATA complexed with 
PMP-pyruvate quinonoid intermediate was generated by using software MOE2014.09 (Chemical 
Computing Group, Montreal, Canada) from the atomic coordinates of the wild-type Ab-R-ATA com-
plexed with PLP in the internal aldimine form. The Schiff linkage of the internal aldimine was removed 
and the quinonoid intermediate was built by adding atoms to the PLP residue. The quinonoid and the 
side chain of Lys188 were energy-minimized using AMBER12:EHT force field with distance-dependent 
dielectric electrostatics, while the other atoms are fixed. The homodimer of Ab-R-ATA was generated by 
using crystallographic symmetry operation.
Preparation of system was also carried out with MOE2014.09. The missing hydrogen atoms were 
generated by Protonate 3D function and energy-minimized using AMBER12:EHT force field with 
distance-dependent dielectric electrostatics. Sodium ions for neutralization and explicit water molecules 
were placed around the protein and the cubic periodic boundary was set at least 4-Å apart from the 
protein surface. The ions and solvent molecules were energy-minimized and applied to 450-ps dynam-
ics simulation in order to be fit to the protein surface appropriately. All atoms in the system were then 
energy-minimized. Gradually decreased tether weight was applied to all non-hydrogen atoms during this 
final minimization steps.
Molecular dynamics simulation was carried out using software NAMD 2.1039 using the input file 
generated by MOE2014.09. The first 1-ns simulation, which was not used for trajectory analysis, was 
performed with the gradually decreasing positional restrains for non-hydrogen atoms. Then, molecular 
dynamics simulation without restrains were performed and used for trajectory analysis. All the dynam-
ics simulations using NAMD were carried out with the time step of 1 fs in NVT ensemble at pressure 
of 101 kPa and at temperature of 300 K without any bonding constraints. Langevin method was used to 
control the constant temperature and pressure. The short range interactions were cut off at 10 Å for van 
der Waals and electrostatic interactions and long-range electrostatic interactions were calculated using 
the particle-mesh Ewald method. Obtained trajectory was analyzed by using software VMD40.
Enzyme assay and analysis. Transaminase activity was assayed by measuring the production of ace-
tophenone, as described previously with minor modifications22. Briefly, the reaction mixture contained 
10 mM (R)-1-phenylethylamine, 10 mM pyruvate or benzylacetone, 100 mM Tris-HCl (pH 8.5), 0.5 mM 
PLP and the enzyme solution. The reaction mixture was incubated at 30 °C for 60 min and stopped 
by adding HCl. The amount of acetophenone formed was determined by HPLC. For determination of 
kinetic parameters, reaction mixtures containing 0.625–2000 mM pyruvate were used. Before initializing 
the reaction by the addition of enzyme, the pH of the reaction solution was adjusted when the pyruvate 
concentration is high. The reaction time was adjusted to 30 min.
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